| Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil … E Cecchin, F Innocenti, M D'Andrea, G Corona, E De Mattia, P Biason, ... Journal of Clinical Oncology 27 (15), 2457-2465, 2009 | 255 | 2009 |
| Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer G Toffoli, E Cecchin, G Gasparini, M D'Andrea, G Azzarello, U Basso, ... Journal of clinical oncology 28 (5), 866, 2010 | 203 | 2010 |
| C677T and A1298C MTHFR polymorphisms, a challenge for antifolate and fluoropyrimidine-based therapy personalisation E De Mattia, G Toffoli European Journal of Cancer 45 (8), 1333-1351, 2009 | 178 | 2009 |
| Pharmacogenetic relevance of MTHFR polymorphisms G Toffoli, E De Mattia Future Medicine Ltd 9 (9), 1195-1206, 2008 | 102 | 2008 |
| A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen E Cecchin, M D'andrea, S Lonardi, C Zanusso, N Pella, D Errante, ... The pharmacogenomics journal 13 (5), 403-409, 2013 | 99 | 2013 |
| Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: toward targeted personalized therapy E De Mattia, E Cecchin, G Toffoli Drug Resistance Updates 20, 39-70, 2015 | 91 | 2015 |
| Tumor response is predicted by patient genetic profile in rectal cancer patients treated with neo-adjuvant chemo-radiotherapy E Cecchin, M Agostini, S Pucciarelli, A De Paoli, V Canzonieri, R Sigon, ... The pharmacogenomics journal 11 (3), 214-226, 2011 | 80 | 2011 |
| New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma M Dal Bo, E De Mattia, L Baboci, S Mezzalira, E Cecchin, YG Assaraf, ... Drug Resistance Updates 51, 100702, 2020 | 76 | 2020 |
| Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma E De Mattia, E Cecchin, M Guardascione, L Foltran, T Di Raimo, ... World journal of gastroenterology 25 (29), 3870, 2019 | 75 | 2019 |
| Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival G Toffoli, P Biason, A Russo, E De Mattia, E Cecchin, CM Hattinger, ... Clinical Cancer Research 15 (10), 3550-3556, 2009 | 69 | 2009 |
| Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment E De Mattia, G Toffoli, J Polesel, M D’Andrea, G Corona, V Zagonel, ... Pharmacogenetics and genomics 23 (10), 549-557, 2013 | 63 | 2013 |
| CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions R Roncato, J Angelini, A Pani, E Cecchin, A Sartore-Bianchi, S Siena, ... International Journal of Molecular Sciences 21 (17), 6350, 2020 | 53 | 2020 |
| The genotype for DPYD risk variants in colorectal cancer patients and the related toxicity management costs in clinical practice G Toffoli, F Innocenti, J Polesel, E De Mattia, F Sartor, CD Fratte, F Ecca, ... Clinical Pharmacology & Therapeutics, 2018 | 45* | 2018 |
| Cost Evaluation of Irinotecan‐Related Toxicities Associated With the UGT1A1* 28 Patient Genotype R Roncato, E Cecchin, M Montico, E De Mattia, L Giodini, A Buonadonna, ... Clinical Pharmacology & Therapeutics 102 (1), 123-130, 2017 | 43 | 2017 |
| MTHFR polymorphisms in gastric cancer and in first-degree relatives of patients with gastric cancer V De Re, R Cannizzaro, V Canzonieri, E Cecchin, L Caggiari, E De Mattia, ... Tumor Biology 31, 23-32, 2010 | 41 | 2010 |
| HLA-G 3’UTR Polymorphisms Impact the Prognosis of Stage II-III CRC Patients in Fluoropyrimidine-Based Treatment M Garziera, E Bidoli, E Cecchin, E Mini, S Nobili, S Lonardi, ... PloS one 10 (12), e0144000, 2015 | 38 | 2015 |
| Pharmacology of epidermal growth factor inhibitors G Toffoli, E De Mattia, E Cecchin, P Biason, S Masier, G Corona The International journal of biological markers 22 (1_suppl4), 24-39, 2007 | 38 | 2007 |
| Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer Treatment A Bignucolo, E De Mattia, E Cecchin, R Roncato, G Toffoli International Journal of Molecular Sciences 18 (7), 1522, 2017 | 35 | 2017 |
| BNC2 is a putative tumor suppressor gene in high-grade serous ovarian carcinoma and impacts cell survival after oxidative stress L Cesaratto, E Grisard, M Coan, L Zandonà, E De Mattia, E Poletto, ... Cell death & disease 7 (9), e2374-e2374, 2016 | 35 | 2016 |
| The molecular and microenvironmental landscape of glioblastomas: Implications for the novel treatment choices F Di Cintio, M Dal Bo, L Baboci, E De Mattia, M Polano, G Toffoli Frontiers in Neuroscience 14, 603647, 2020 | 31 | 2020 |
Enrico MiniProfessore在 unifi.it 的电子邮件经过验证
